Bluebird’s star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech startups
→ Every biotech enjoys a good success story, and bluebird bio $BLUE got their writeup in the New England Journal of Medicine. Patient 1204 in bluebird’s program for LentiGlobin gene therapy program has had more than 15 months of followup, and his physicians say that the teenager has been free of the painful symptoms of sickle cell disease, able to lead a normal life and stop painful transfusions. That’s all a positive, but bluebird’s gene therapy has also proven to be somewhat variable among patients. One success story does not make for a successful therapy, but it’s still a plus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.